In the latest trading session, 0.9 million Gossamer Bio Inc. (NASDAQ:GOSS) shares changed hands as the company’s beta touched 1.20. With the company’s most recent per share price at $0.92 changing hands around $0.0 or -0.38% at last look, the market valuation stands at $196.64M. GOSS’s current price is a discount, trading about -1403.26% off its 52-week high of $13.83. The share price had its 52-week low at $0.84, which suggests the last value was 8.7% up since then. When we look at Gossamer Bio Inc.’s average trading volume, we note the 10-day average is 3.13 million shares, with the 3-month average coming to 2.45 million.
Analysts gave the Gossamer Bio Inc. (GOSS) stock a consensus recommendation rating of an Overweight, calculated at a mean rating of 2.40. If we narrow down to specifics, the data shows that 1 out of 11 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 4 recommended GOSS as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Gossamer Bio Inc.’s EPS for the current quarter is expected to be -$0.26.
Gossamer Bio Inc. (NASDAQ:GOSS) trade information
Instantly GOSS was in red as seen in intraday trades today. With action -5.47%, the performance over the past five days has been red. The drop to weekly highs of 1.0100 on Friday, 09/15/23 subtracted -0.38% to the stock’s daily price. The company’s shares are showing year-to-date downside of -57.75%, with the 5-day performance at -5.47% in the red. However, in the 30-day time frame, Gossamer Bio Inc. (NASDAQ:GOSS) is -10.11% down. Looking at the short shares, we see there were 19.77 million shares sold at short interest cover period of 13.11 days.
The consensus price target for the stock as assigned by Wall Street analysts is $5.31, meaning bulls need an upside of 82.67% from its recent market value. According to analyst projections, GOSS’s forecast low is $1.25 with $15.00 as the target high. To hit the forecast high, the stock’s price needs a -1530.43% plunge from its current level, while the stock would need to soar -35.87% for it to hit the projected low.
Gossamer Bio Inc. (GOSS) estimates and forecasts
Data shows that the Gossamer Bio Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -4.60% over the past 6 months, a 46.49% in annual growth rate that is considerably higher than the industry average of 11.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Gossamer Bio Inc. will rise 60.00%, while the growth in revenue is estimated to hit 54.20% for the next quarter.
The 2023 estimates are for Gossamer Bio Inc. earnings to increase by 13.30%, but the outlook for the next 5-year period is at 5.20% per year.
Gossamer Bio Inc. is expected to release its next quarterly earnings report between November 01 and November 06.
Gossamer Bio Inc. (NASDAQ:GOSS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 5.40% of Gossamer Bio Inc. shares while 90.37% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 95.52%. There are 90.37% institutions holding the Gossamer Bio Inc. stock share, with HHLR Advisors, LTD the top institutional holder. As of Jun 29, 2023, the company held 2.21% of the shares, roughly 4.97 million GOSS shares worth $5.97 million.
Millennium Management Llc holds the second largest percentage of outstanding shares, with 1.87% or 4.21 million shares worth $5.05 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 2.06 million shares estimated at $2.47 million under it, the former controlled 0.91% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.50% of the shares, roughly 1.12 million shares worth around $1.35 million.